Cargando…
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
The 2020 COVID-19 pandemic has disrupted Alzheimer’s disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer’s Disease (...
Autores principales: | Kaye, Jeffrey, Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., Vellas, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244451/ https://www.ncbi.nlm.nih.gov/pubmed/34585227 http://dx.doi.org/10.14283/jpad.2021.36 |
Ejemplares similares
-
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020) -
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021) -
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022) -
Task Force on Reintegration
Publicado: (1991) -
Task Force on Reintegration Guarantees for the pensions of the CERN personnel in the event of the dissolution of the Organization Third Progress Report by the Chairman (Resolution Appendix 1)
Publicado: (1995)